Your session is about to expire
← Back to Search
Study Summary
This trial looks at the safety and tolerability of a drug called pimavanserin when used to treat schizophrenia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 4 trial • 6 Patients • NCT04188392Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I understand the study and have signed the consent form.I do not have any serious health issues that would prevent me from participating in the study.My main antipsychotic medication is one of the specified drugs.I am not pregnant or breastfeeding and will use birth control.I have a history or risk of long QT syndrome.
- Group 1: Drug - Pimavanserin
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many test subjects are needed for this clinical trial?
"That is correct, the information on clinicaltrials.gov verifies that this study is currently looking for participants. The posting date was January 1st 2017 and the most recent update was on August 30th 2022. They are recruiting 500 patients from 2 different locations."
Is this a new or unique study?
"Pimavanserin has been the focus of 6 clinical trials since 2017, with the first being sponsored by ACADIA Pharmaceuticals Inc. After this initial trial involving 500 patients, Pimavanserin received Phase 3 drug approval in 2017. Currently, there are 101 cities and 20 countries with active studies on Pimavanserin's effects."
Can Pimavanserin have negative consequences for human health?
"Pimavanserin has received a score of 3 for safety from our team at Power. This is because it is a phase 3 trial, which suggests that not only does this drug have some evidence supporting efficacy, but also multiple rounds of data affirming its safety."
Can new patients still enroll in this research project?
"The listed information on clinicaltrials.gov says that this trial is looking for participants right now. The first posting was on 1/1/2017, with the most recent update taking place on 8/30/2022. They need 500 people total from 2 different locations."
What other scientific investigations have included Pimavanserin?
"Pimavanserin was first studied in 2017 at SPHI. Since the completion of the original clinical trial, there have been 18 more. Presently, there are 6 live trials taking place across Jamaica and New york."
Share this study with friends
Copy Link
Messenger